USDT Casino Bonuses-TOSPIN Online Casino & Sports Betting - Play & Bet Online

<dfn id="fnsbx"></dfn>

        1. Accessibility helpSkip to navigationSkip to contentSkip to footer
          • Sign In
          • Subscribe
          Open side navigation menuOpen search bar
          Financial Times
          SubscribeSign In
          • Home
          • World
            Sections
            • World Home
            • Middle East war
            • Global Economy
            • UK
            • US
            • China
            • Africa
            • Asia Pacific
            • Emerging Markets
            • Europe
            • War in Ukraine
            • Americas
            • Middle East & North Africa
            Most Read
            • Trump defends gift of 747 jet from Qatar as new Air Force One
            • China and US agree to slash tariffs
            • Starmer unveils migration curbs
            • Trump seeks bromance and billions as he heads to Gulf
            • Trump vows to lower US drug prices by up to 80%
          • US
            Sections
            • US Home
            • US Economy
            • US Companies
            • US Politics & Policy
            Most Read
            • Trump defends gift of 747 jet from Qatar as new Air Force One
            • China and US agree to slash tariffs
            • Trump seeks bromance and billions as he heads to Gulf
            • Trump vows to lower US drug prices by up to 80%
            • US claims ‘substantial progress’ after trade talks with China
          • Companies
            Sections
            • Companies Home
            • Energy
            • Financials
            • Health
            • Industrials
            • Media
            • Professional Services
            • Retail & Consumer
            • Tech Sector
            • Telecoms
            • Transport
            Most Read
            • Trump vows to lower US drug prices by up to 80%
            • Evercore poaches top European Citigroup dealmaker
            • EV battery maker CATL to raise at least $4bn
            • The myth of the genius hacker
            • Why can’t more financial heavyweights write letters like Warren Buffett?
          • Tech
            Sections
            • Tech Home
            • Artificial intelligence
            • Semiconductors
            • Cyber Security
            • Social Media
            Most Read
            • The myth of the genius hacker
            • LLM vs LLB: the case for junior lawyers is undermined by AI
            • OpenAI negotiates with Microsoft to unlock new funding and future IPO
            • How AI agents compare on routine work tasks
            • Low-cost India seen as potential regional hub in data centre boom
          • Markets
            Sections
            • Markets Home
            • Alphaville
            • Markets Data
            • Crypto
            • Capital Markets
            • Commodities
            • Currencies
            • Equities
            • Monetary Policy Radar
            • Wealth Management
            • Moral Money
            • ETF Hub
            • Fund Management
            • Trading
            Most Read
            • EV battery maker CATL to raise at least $4bn
            • Funds for wealthy investors snap up expensive private equity stakes
            • US tariff policy accelerates deeper structural changes
            • US beef prices extend surge as ranchers face thinnest herds in 70 years
            • Saudi Aramco cuts its dividend by $10bn
          • Climate
          • Opinion
            Sections
            • Opinion Home
            • Columnists
            • The FT View
            • The Big Read
            • Lex
            • Obituaries
            • Letters
            Most Read
            • Why ‘Make Hollywood Great Again’ makes sense
            • The EU needs a new geopolitical compass
            • The myth of the genius hacker
            • Life is too important not to laugh at it
            • Why can’t more financial heavyweights write letters like Warren Buffett?
          • Lex
          • Work & Careers
            Sections
            • Work & Careers Home
            • Business School Rankings
            • Business Education
            • Europe's Start-Up Hubs
            • Entrepreneurship
            • Recruitment
            • Business Books
            • Business Travel
            • Working It
            Most Read
            • Why can’t more financial heavyweights write letters like Warren Buffett?
            • How AI agents compare on routine work tasks
            • Scenario planning is getting a stress test
            • It’s LinkedIn — no one expects you to be authentic
            • Number of entrepreneurs closing UK businesses hits highest level since pandemic
          • Life & Arts
            Sections
            • Life & Arts Home
            • Arts
            • Books
            • Food & Drink
            • FT Magazine
            • House & Home
            • Style
            • Puzzles
            • Travel
            • FT Globetrotter
            Most Read
            • Why ‘Make Hollywood Great Again’ makes sense
            • Three things we learned about Sam Altman by scoping his kitchen
            • Life is too important not to laugh at it
            • Taiwan TV drama to give public a visceral vision of war with China
            • Trump’s casino rococo White House and the politics of ornamentation
          • HTSI
          MenuSearch
          • Home
          • World
          • US
          • Companies
          • Tech
          • Markets
          • Climate
          • Opinion
          • Lex
          • Work & Careers
          • Life & Arts
          • HTSI
          Financial Times
          SubscribeSign In

          BioNTech

          • Wednesday, 13 November, 2024
            BioNTech strikes $950mn deal for Chinese drugmaker Biotheus

            Acquisition is latest example of western drugmakers turning to China to tap innovation

            A portrait of U?ur ?ahin, dressed in a white coat, sitting on a stool in a laboratory
          • Wednesday, 2 October, 2024
            Artificial intelligence
            DeepMind and BioNTech build AI lab assistants for scientific research

            Artificial intelligence used to help researchers plan experiments and better predict outcomes

            Montage of Google DeepMind and BioNTech logos with a finger on a smartphone in the foreground and semiconductor chip design in the background
          • Thursday, 29 August, 2024
            The cost of cracking cancer
            The Covid-era tech that could reinvent cancer care

            Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology

          • Tuesday, 27 August, 2024
            The cost of cracking cancer
            The cost of cracking cancer: what the $1tn race for a cure leaves behind

            The first in an FT series looking at the new energy behind the fight for cancer cures

            A montage showing a scientist wearing protective gear, including a hairnet, mask, and gloves, handling a syringe. To the right, a petri dish with nematodes visible inside. The background features an image of pancreatic cancer cells.
          • Friday, 16 August, 2024
            Pharmaceuticals sector
            BioNTech/Pfizer Covid and flu combo vaccine falters in late-stage trial

            Jab makers fall behind Moderna in post-pandemic market with disappointing results

            A close up shot of a Covid vaccine being administered
          • Tuesday, 2 July, 2024
            Moderna
            Moderna secures partial victory in Covid vaccine legal fight

            Pfizer and BioNTech infringed pharmaceutical group’s mRNA patent, High Court in London rules

            A patient receives a Moderna jab
          • Wednesday, 22 May, 2024
            Pharmaceuticals sector
            Shares in biotechs surge as two new human bird flu infections emerge

            Fears of growing outbreak drive revival in vaccine group stocks which have been out of favour since pandemic ended

            A person touches a test tube labelled ‘Bird Flu’
          • Friday, 17 May, 2024
            Moderna
            Moderna wins Covid jab patent dispute over Pfizer and BioNTech

            Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals

          • Monday, 22 April, 2024
            News in-depthCovid-19 vaccines
            Covid vaccine makers to clash in London over mRNA patent dispute

            Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform

            A woman receiving a dose of Moderna’s Covid vaccine
          • Monday, 6 November, 2023
            BioNTech cuts revenue forecast on lower demand for Covid jabs

            German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting

            A patient receiving a vaccine dose
          • Monday, 16 October, 2023
            BioNTech writes down €900mn on Covid-19 vaccines

            Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic

            A dose of the BioNtech/Pfizer Covid vaccine is administered to a person at a vaccination centre
          • Tuesday, 3 October, 2023
            News in-depthPfizer Inc
            Covid vaccine winners suffer reversal of fortune

            Companies have yet to provide investors with convincing post-pandemic strategies

            A montage of a nurse preparing a Covid-19 Pfizer vaccine, and the BioNTech and Moderna logos
          • Sunday, 11 June, 2023
            BioNTech faces hundreds of German compensation claims for Covid-19 jab

            Pharmaceuticals producer in first court hearing on Monday

            A patient receives the Pfizer/BioNTech vaccine in Leipzig, Germany
          • Sunday, 30 April, 2023
            Covid-19 vaccines
            BioNTech/Pfizer’s mooted EU deal for 70mn Covid shots threatens rivals

            European health officials have advocated portfolio diversity to help fight different variants

            A teenager receives a Pfizer COVID-19 vaccine at a vaccination centre
          • Monday, 27 March, 2023
            BioNTech forecasts slump in sales as demand for Covid jab wanes

            Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

            A woman receives a booster dose of the BioNTech-Pfizer coronavirus vaccine
          • Tuesday, 10 January, 2023
            BioNTech buys UK AI start-up InstaDeep in £562mn deal

            Covid vaccine maker looks to use machine learning to help discover new treatments

            BioNTech’s chief U?ur ?ahin
          • Friday, 6 January, 2023
            Medical science
            UK signs deal with BioNTech for cutting-edge cancer trials

            Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS

            An employee holds up a vial of an oncological product under development at the BioNTech’s research institute in Mainz, Germany
          • Monday, 2 January, 2023
            LexDrugs research
            Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony Premium?content

            Success in battle against Covid does not ensure success against tumours, but should narrow the odds

            A nurse prepares a dose of Moderna’s Covid vaccine
          • Monday, 7 November, 2022
            Profits drop at BioNTech as Covid vaccine demand wanes

            Fall from €3.2bn in the third quarter of 2021 to €1.8bn

            A BioNTech worker in Marburg, Germany
          • Sunday, 16 October, 2022
            Covid-19 vaccines
            Vaccine makers face revenue slump as demand falls for Covid jabs

            Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic

            A woman receives a dose of the BioNTech/Pfizer vaccine
          • Thursday, 13 October, 2022
            InterviewCovid-19 vaccines
            Beijing’s failure to import mRNA Covid jabs ‘mind-boggling’, says BeiGene executive

            Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy

            A researcher at a BeiGene laboratory
          • Wednesday, 28 September, 2022
            Behind the Money podcast18 min listen
            Who will pay for the next Covid vaccines?

            Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic

          • Wednesday, 31 August, 2022
            Covid-19 vaccines
            US approves Omicron vaccines from Moderna and BioNTech/Pfizer

            FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections

            A medical worker prepares to administer a BioNTech/Pfizer Covid vaccine booster
          • Friday, 26 August, 2022
            Covid-19 vaccines
            Moderna accuses BioNTech/Pfizer of copying mRNA technology

            US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic

            Syringes with needles displayed in front of a Moderna logo
          • Monday, 22 August, 2022
            Covid-19 vaccines
            Pfizer and BioNTech ask US regulator to authorise variant-specific jab

            Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials

            Pfizer chief executive Albert Bourla speaks at an event
          Previous page1Next page

          Useful links

          Support

          View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareersSuppliers

          Legal & Privacy

          Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

          Services

          Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

          Tools

          PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

          Community & Events

          FT Live EventsFT ForumsFT Leaders Academy

          More from the FT Group

          Markets data delayed by at least 15 minutes. ? THE FINANCIAL TIMES LTD 2025. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
          The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
          Edition:International
          UK
          Subscribe for full access

          Top sections

          • Home
          • World
            • Middle East war
            • Global Economy
            • UK
            • US
            • China
            • Africa
            • Asia Pacific
            • Emerging Markets
            • Europe
            • War in Ukraine
            • Americas
            • Middle East & North Africa
          • US
            • US Economy
            • US Companies
            • US Politics & Policy
          • Companies
            • Energy
            • Financials
            • Health
            • Industrials
            • Media
            • Professional Services
            • Retail & Consumer
            • Tech Sector
            • Telecoms
            • Transport
          • Tech
            • Artificial intelligence
            • Semiconductors
            • Cyber Security
            • Social Media
          • Markets
            • Alphaville
            • Markets Data
            • Crypto
            • Capital Markets
            • Commodities
            • Currencies
            • Equities
            • Monetary Policy Radar
            • Wealth Management
            • Moral Money
            • ETF Hub
            • Fund Management
            • Trading
          • Climate
          • Opinion
            • Columnists
            • The FT View
            • The Big Read
            • Lex
            • Obituaries
            • Letters
          • Lex
          • Work & Careers
            • Business School Rankings
            • Business Education
            • Europe's Start-Up Hubs
            • Entrepreneurship
            • Recruitment
            • Business Books
            • Business Travel
            • Working It
          • Life & Arts
            • Arts
            • Books
            • Food & Drink
            • FT Magazine
            • House & Home
            • Style
            • Puzzles
            • Travel
            • FT Globetrotter
          • Personal Finance
            • Property & Mortgages
            • Investments
            • Pensions
            • Tax
            • Banking & Savings
            • Advice & Comment
          • HTSI
          • Special Reports

          FT recommends

          • Alphaville
          • FT Edit
          • Lunch with the FT
          • FT Globetrotter
          • #techAsia
          • Moral Money
          • Visual and data journalism
          • Newsletters
          • Video
          • Podcasts
          • News feed
          • FT Schools
          • FT Live Events
          • FT Forums
          • FT Leaders Academy
          • myFT
          • Portfolio
          • FT Digital Edition
          • Crossword
          • Our Apps
          • Help Centre
          • Subscribe
          • Sign In

          感谢您访问我们的网站,您可能还对以下资源感兴趣:

          USDT Casino Bonuses
          TOSPIN TOSPIN TOSPIN TOSPIN
              <address id="c4918"></address>
            1. <pre id="c4918"></pre>

                <dfn id="c4918"><var id="c4918"></var></dfn>
                  <sup id="c4918"><menu id="c4918"><acronym id="c4918"></acronym></menu></sup>
                1. <dfn id="c4918"></dfn>
                    <sub id="c4918"></sub>